![]() TPX-100: OrthoTrophix Presents More Evidence for Disease Modification in Knee Osteoarthritis in a New Abstract Published in Osteoarthritis & Cartilage JournalOakland, Calif., May 12, 2020—OrthoTrophix, Inc., a privately held biopharmaceutical company, announced today that the Company has demonstrated more evidence for disease modification in knee osteoarthritis (OA) patients treated with An abstract entitled, “Study In this study, three-dimensional (3D) shapes of the femur in knees of OA patients were measured with MRI at baseline (before treatment) and 6 and 12 months after treatment. As previously reported, pathological 3D shape changes in the femur in As reported previously, “TPX-100 has shown concordant, positive results in imaging markers and in clinical outcomes. The key dots have been connected,” commented Dr. Dawn McGuire, OrthoTrophix’ Chief Medical Officer. “Femoral bone shape change has been shown to predict OA onset, progression and the need for knee replacement. Our clinical data suggest that reducing pathological femoral bone shape change and stabilizing knee cartilage go hand in hand with functional improvements for patients. In addition, we previously showed that a robust reduction in knee pain frequency after About OrthoTrophix, Inc.OrthoTrophix, Inc., based in Oakland, California, is a privately held biopharmaceutical company focused on development and commercialization of a new class of Disease Modifying Osteoarthritis Drug (DMOAD). Founded by three co-founders in 2011, the primary focus of OrthoTrophix has been regeneration and repair of cartilage and underlying bones in the knee and other joints with its novel proprietary compounds. This press release contains “forward-looking” statements. These statements involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements include statements regarding product development and cannot be guaranteed. OrthoTrophix undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect OrthoTrophix’ business. Company ContactYoshi Kumagai
# # #
|